HOME > Clinical Trial

Clinical Trial

Clinical studies in progress

As of March 2019

Study on Ovarian cancer

Study name: JGOG3020 (NCT04063527)
Subject  Patients with surgical stage I epithelial ovarian cancer
Treatment  Phase III, randomized, comparative study of surgery plus adjuvant chemotherapy and surgery alone.
Accrual Period  July 2012 - June 2024
Target number of patients  Number per group: 230  Total number: 460
Study name: JGOG3024
Subject  BRCA1 and/or BRCA2 variant carriers
Treatment  To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying BRCA1/2 variants.
Accrual Period  April 2017 - March 2027
Target number of patients  600
Study name: JGOG3025
Subject  Ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)
Treatment  To investigate the frequency and clinical significance of Homologous Recombination Deficiency (HRD) in Japanese patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)
Accrual Period  Janualy 2017 - March 2019
Target number of patients  700

Study on Supportive care

Study name: JGOG9004
Subject  cervical cancer
Treatment  To reveal sexuality change after cancer treatment among Japanese cervical cancer patients using Female Sexual Function Index (FSFI) and Hospital Anxiety and Depression Scale (HADS).
Accrual Period  September 2018 - August 2019
Target number of patients  150
  • Organization Chart
  • Board of Directors
  • Crinical Trial
  • Achievement
  • JGOG COI Policy
  • Newsletter
  • Related Links

JGOG Administration Office
4F, Komatsu Building, 6-22, Kagurazaka, Shinjuku-ku,
Tokyo, 162-0825,
E-mail : info-e@jgog.gr.jp